Histogenics

News

US biotechs Ocugen and Histogenics have announced plans to merge, creating a specialist in drugs and gene therapies for ocular diseases.

News

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.